Wenting Gu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wenting Gu has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Fanzhu Li
School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, China
1 shared publication - Ji-Gang Piao
College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China
1 shared publication - Li He
School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China
1 shared publication - Tianxiang Yue
School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China
1 shared publication - WeiYe Ren
School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China
1 shared publication - WeiYi Cheng
College of Pharmaceutical Sciences, Zhejiang Chinese Medical University
1 shared publication
Latest Publications
- Open Access
- 17 October 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (10) , 2483
Recent Advances in Mesoporous Silica Nanoparticles Delivering siRNA for Cancer Treatment
Silencing genes using small interfering (si) RNA is a promising strategy for treating cancer. However, the curative effect of siRNA is severely constrained by low serum stability and cell membrane permeability. Therefore, improving the delivery efficiency of siRNA for cancer treatment is a research hotspot. Recently, mesoporous silica nanoparticles (MSNs) have emerged as bright delivery vehicles for nucleic acid drugs. A comprehensive understanding of the design of MSN-based vectors is crucial for the application of siRNA in cancer therapy. We discuss several surface-functionalized MSNs’ advancements as effective siRNA delivery vehicles in this paper. The advantages of using MSNs for siRNA loading regarding considerations of different shapes, various options for surface functionalization, and customizable pore sizes are highlighted. We discuss the recent investigations into strategies that efficiently improve cellular uptake, facilitate endosomal escape, and promote cargo dissociation from the MSNs for enhanced intracellular siRNA delivery. Also, particular attention was paid to the exciting progress made by combining RNAi with other therapies to improve cancer therapeutic outcomes.
- 17 October 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (10) , 2483
Open AccessRecent Advances in Mesoporous Silica Nanoparticles Delivering siRNA for Cancer Treatment
Silencing genes using small interfering (si) RNA is a promising strategy for treating cancer. However, the curative effect of siRNA is severely constrained by low serum stability and cell membrane permeability. Therefore, improving the delivery efficiency of siRNA for cancer treatment is a research hotspot. Recently, mesoporous silica nanoparticles (MSNs) have emerged as bright delivery vehicles for nucleic acid drugs. A comprehensive understanding of the design of MSN-based vectors is crucial for the application of siRNA in cancer therapy. We discuss several surface-functionalized MSNs’ advancements as effective siRNA delivery vehicles in this paper. The advantages of using MSNs for siRNA loading regarding considerations of different shapes, various options for surface functionalization, and customizable pore sizes are highlighted. We discuss the recent investigations into strategies that efficiently improve cellular uptake, facilitate endosomal escape, and promote cargo dissociation from the MSNs for enhanced intracellular siRNA delivery. Also, particular attention was paid to the exciting progress made by combining RNAi with other therapies to improve cancer therapeutic outcomes.